
|Videos|December 13, 2021
Ongoing Clinical Trials Look to Assess Optimization or Combination Treatments of Asciminib in CML
Myriam Mendila, MD, chief medical officer and global head of medical affairs at Novartis Oncology, discusses ongoing trials assessing efficacy and safety of asciminib in the treatment of chronic myeloid leukemia.
Advertisement
Pharmacy Times interviewed Myriam Mendila, MD, chief medical officer and global head of medical affairs at Novartis Oncology, on her presentation at the 63rd American Society of Hematology Annual Meeting & Exposition on new longer-term efficacy and safety data from the pivotal phase 3 ASCEMBL study for FDA-approved asciminib.
During the interview, Mendila discussed ongoing trials assessing efficacy and safety of asciminib in the treatment of chronic myeloid leukemia.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
EPCORE DLBCL-1 Trial Demonstrates Durable Responses, PFS Benefit With Epcoritamab in RR LBCL
2
FDA Adds a New Sunscreen to the OTC Repertoire
3
OTC Guide: Thirty Years Strong
4
FDA Approves Capivasertib Plus Abiraterone and Prednisone for Prostate Cancer
5






























































































































